Rapid Research in Diagnostics Development for Tuberculosis TB Network Study Evaluating New TB Diagnostic and Drug Resistance Tests in Adults

What this Trial Is About

Researchers are evaluating new diagnostic tests to improve the detection and management of tuberculosis TB, a disease that leaves many undiagnosed and causes significant mortality worldwide. This study, known as the Rapid Research in Diagnostics Development for TB Network R2D2 TB Network, aims to assess early-stage TB triage, diagnostic, and drug resistance tests in real-world clinical settings across multiple countries. The goal is to identify faster, simpler, and less expensive tools to reduce the current gaps in timely TB diagnosis and treatment initiation. The study involves testing various novel diagnostic methods, including sputum-based and non-sputum biomarker tests, molecular assays, breath-based tests, and artificial intelligence tools to analyze images and sounds related to TB diagnosis. These tests will be compared to established reference standards like sputum culture and molecular resistance testing. The study also evaluates the usability of these tests through observations and surveys of health workers. Participants include adults with symptoms or risk factors for TB, and patients with rifampin-resistant TB for drug susceptibility test evaluations. Participants will undergo diagnostic testing and clinical assessments, with follow-up visits scheduled to monitor test performance and usability. Researchers will measure the sensitivity and specificity of these novel tests over a seven-month period. The study also tracks the ability of health workers to effectively use the new diagnostic tools. Overall participation duration varies by individual, and the study aims to provide comprehensive data to enhance TB diagnosis and treatment worldwide.

Rapid Research in Diagnostics Development for TB Network